Dr Leung is the founder, Chairman and Chief Executive Officer of SinoMab BioScience Limited (“SinoMab”). Currently, he is also a Member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited.
Dr Leung has over 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. He was the first scientist to successfully develop humanised anti-CD22 antibody and introduce the concept of “Functional Humanisation”.
Prior to founding SinoMab, he held positions as the Executive Director of a leading US antibody-drug conjugate company, and the Managing Director of The Hong Kong Institute of Biotechnology Limited. Dr Leung currently also serves as an Adjunct Professor at The Hong Kong University of Science and Technology.
Dr Leung obtained his BSc and MPhil in biochemistry, as well as EMBA from CUHK. He earned his DPhil in molecular biology from the University of Oxford in the UK in May 1989. He received a Howard Hughes Medical Institute fellowship at Yale University in the US for his postdoctoral training in molecular immunology from July 1989 to June 1991.